Ovarian Cancer Heat Map and Analysis 2015-2022 – Research and Markets

DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ovarian
Cancer – Heat Map and Analysis”
report to their offering.

Ovarian Cancer (OC) is the fifth most common malignancy diagnosed in
women, and the most common gynecological cancer, with an estimated
225,000 new cases diagnosed globally in 2008. Rates are particularly
high in developed countries, and especially in Northern Europe. However,
substantial improvements in the treatment of OC have been made in recent
decades, through the introduction of platinum-based compounds, and
improvements in surgery.

This has resulted in an increase in the percentage of patients that
survive for five years, from approximately 20% in the 1970s, to the
current rate of 45%. However, there have been no significant
improvements in the treatment of the disease in recent years, with
platinum-based compounds remaining the standard of care for first- and
usually second-line treatment.

The differences between many of these products are relatively nuanced,
and must be understood fully by companies seeking to position a novel
drug in this market. This tabular heatmap framework, designed to provide
an easily digestible summary of these clinical characteristics, provides
detailed information on all late-stage clinical trial results for
products in the OC market and late-stage pipeline. These are split along
therapy lines, and are therefore reflective of the treatment algorithm.

All safety and efficacy endpoints reported in these trials are
displayed, for both the drug and comparison groups. In addition, key
study characteristics such as the size, composition and patient segment
of the study population are provided. These results are presented in a
visually accessible, color-coded manner in order to maximize ease of use.

The accompanying text provides a detailed analysis of the clinical
benchmarks set by the current market landscape, and the anticipated
changes to these benchmarks, and to the treatment algorithm, as a result
of the late-stage pipeline.


– What are the clinical characteristics of currently approved therapies
for OC, in terms of specific safety and efficacy parameters?

– What are the key unmet needs in this indication, and which clinical
safety and efficacy parameters are the most closely linked to them?

– What types of therapy are in development and what modes of action do
they employ?

– What impact will pipeline products have on the first-line, maintenance
and recurrent disease market segments?

Key Topics Covered:

1. Table of Contents

2. Introduction

2.1 Report Guidance

3. Marketed Products

3.1 First-Line Therapy

3.2 Maintenance Therapy

3.3 Recurrent Disease

4. Pipeline Products

4.1 Changes to First-Line Therapy, 2015-2022

4.2 Changes to Maintenance Therapy, 2015-2022

4.3 Changes to Recurrent Disease, 2015-2022

5. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/lr85zf/ovarian_cancer


Research and Markets
Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Topics: Women’s